These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39394846)

  • 1. Preferences of patients and physicians in the United States for relapsed/refractory follicular lymphoma treatments.
    Thomas C; Marsh K; Trapali M; Krucien N; Worth G; Cockrum P; Lycett D
    Cancer Med; 2024 Oct; 13(19):e70177. PubMed ID: 39394846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
    Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
    Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
    Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
    Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: Discrete choice experiment eliciting preferences in real-world study "VOTE".
    Rosenow F; Winter Y; Leunikava I; Brunnert M; Joeres L; Sutphin J; Boeri M; Smith J; Villani F; Brandt C
    Epilepsia; 2022 Feb; 63(2):451-462. PubMed ID: 34921391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
    González JM; Doan J; Gebben DJ; Boeri M; Fishman M
    Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment.
    Shafey M; Lupichuk SM; Do T; Owen C; Stewart DA
    Bone Marrow Transplant; 2011 Jul; 46(7):962-9. PubMed ID: 20935681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
    Oluwole OO; Ray MD; Zur RM; Ferrufino CP; Doble B; Patel AR; Bilir SP
    Front Immunol; 2024; 15():1393939. PubMed ID: 38855109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' Preferences for Systemic Lupus Erythematosus Treatments-A Discrete Choice Experiment.
    Collacott H; Phillips-Beyer A; Krucien N; Flamion B; Marsh K
    Patient; 2024 May; 17(3):287-300. PubMed ID: 38270788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments.
    Sun H; Wang H; Shi L; Wang M; Li J; Shi J; Ni M; Hu X; Chen Y
    BMJ Open; 2020 Feb; 10(2):e032336. PubMed ID: 32051302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
    Mühlbacher AC; Nübling M
    Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia.
    Fifer S; Godsell J; Opat S; Hamad N; Lasica M; Forsyth C; Morand L; Smeaton E; Winton S; Puig A; McGeachie M
    BMC Cancer; 2024 Jul; 24(1):831. PubMed ID: 38992616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment.
    Wong XY; Lim AQJ; Shen Q; Chia JWK; Chew MH; Tan WS; Wee HL
    Curr Med Res Opin; 2020 Oct; 36(10):1677-1686. PubMed ID: 32609014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor-mutant non-small cell lung cancer.
    Hata A; Fifer S; Hasegawa K; Ando E; Kasahara-Kiritani M; Takahashi M; Ordman R; Toh L; Inoue A
    Cancer Med; 2024 Jan; 13(1):e6777. PubMed ID: 38196301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient preferences for heart valve disease intervention.
    Fifer S; Keen B; Guilbert-Wright P; Yamabe K; Murdoch DJ
    Health Expect; 2024 Feb; 27(1):e13929. PubMed ID: 38050462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
    Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
    Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
    Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.
    Kanters S; Ball G; Kahl B; Wiesinger A; Limbrick-Oldfield EH; Sudhindra A; Snider JT; Patel AR
    BMC Cancer; 2023 Jan; 23(1):74. PubMed ID: 36690960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment.
    Ravelo A; Myers K; Brumble R; Bussberg C; Koffman B; Manzoor BS; Biondo JML; Mansfield C
    Future Oncol; 2024; 20(28):2059-2070. PubMed ID: 38861284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
    Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
    Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer.
    Bridges JF; la Cruz M; Pavilack M; Flood E; Janssen EM; Chehab N; Fernandes AW
    Future Oncol; 2019 Dec; 15(34):3895-3907. PubMed ID: 31621403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.